Recent Finacing
Recent Raise
Covagen is a Zurich-based preclinical biotech using a proprietary Fynomer/FynomAb protein‑engineering platform to develop bi- and trispecific therapeutics, including COVA322, a TNF/IL‑17A bispecific for inflammatory diseases and cancer.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors